CG Oncology Raises $120M in Series E Financing

CG Oncology, an Irvine, CA-based oncolytic immunotherapy firm, raised $120M in Series E funding.

The spherical was co-led by ORI Capital, Longitude Capital and Decheng Capital, with participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group and Sirona Capital. In reference to the financing, Brian Liu, M.D., Principal from Longitude Capital, will be a part of the corporate’s board of administrators.

The firm intends to make use of the funds to advance its medical packages in bladder most cancers in direction of FDA approval in addition to broaden the scope of its pipeline to handle unmet medical wants in urologic most cancers, such because the first-line setting in Bacillus Calmette-Guérin (BCG)-naïve, intermediate-risk non-muscle invasive bladder most cancers (NMIBC) sufferers.

Led by CEO Arthur Kuan, CG Oncology is an oncolytic immunotherapy firm centered on creating bladder-saving therapeutics for sufferers with urologic most cancers. Its lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the remedy of BCG-unresponsive non-muscle invasive bladder most cancers. CG0070 can also be in a Phase 2 research together with KEYTRUDA® (pembrolizumab) in the identical indication. Other sorts of bladder most cancers are being evaluated with CG0070 together with OPDIVO® (nivolumab). 

The firm has secured a complete of over $200M in funding up to now.



Leave a Comment